Benitec s Move to US Proceeds Apace as Execs Eye M&A Possibilities, Development Programs | GenomeWeb

Last spring, Benitec initiated a reorganization plan — designed to turn it into a US-based and publicly traded RNAi drug developer — by exclusively licensing to Promega its DNA-directed RNAi technology for areas outside of human therapeutics. (See GenomeWeb News, 4/17/2003). With that deal poised to bear fruit for Benitec in the form of royalties from Promega on ddRNAi-related sublicenses and research product sales, the Australian company’s two top executives are now in the US scouting out investment banks that could help it move closer to its goal.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.